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patients treated with or without the use of a UAS to deter-
mine the impact on stone-free rates (SFRs).
Results Of 2239 patients treated with flexible URS, 1494 
(67 %) patients were treated with the use of a UAS and 745 
(33 %) without a UAS. The IPWRA analyses conducted on 
1827 patients with complete data and based on treatment 
and outcome models showed that if URS procedures were 
performed without the use of an UAS, the average stone-
free rate would be 0.504 compared with 0.753 with a UAS. 
This average treatment effect of 0.248 was not significant 
(P = 0.604). Using IPWRA analysis on only the treated 
population in the estimations revealed no significant dif-
ference between using and not using a UAS (31 %; ATET: 
0.311; P = 0.523).
Conclusions The study showed no difference in SFR 
when a UAS was used or not. Whereas UAS did not 
increase the risk of ureteral damage or bleeding, postopera-
tive infectious complications were reduced.
Keywords Ureteroscopy · Renal stones · Ureteral access 
sheath treatment outcome · Complications
Introduction
The ureteral access sheath (UAS) has been developed on 
the same concept as AMPLATZ sheath for percutaneous 
nephrolithotomy, i.e., to allow direct access to the kidney 
and to decrease the intra-renal pressure during upper-tract 
endourological procedures. It has become increasingly pop-
ular as it offers a number of potential advantages includ-
ing facilitation of access to the renal collecting systems, 
multiple entry and reentry, decreased intra-renal pressure, 
and improved drainage around the scope [1–5]. The UAS 
has the added advantage of allowing passive elimination of 
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Purpose To describe the differences in the treatment and 
the outcomes of renal stones treated with flexible ureteros-
copy (URS) either with or without the support of a ureteral 
access sheath (UAS).
Methods The Clinical Research Office of the Endouro-
logical Society URS Global Study involved the collec-
tion of prospective data from consecutive patients treated 
with URS at centers around the world over a 1-year 
period. Baseline characteristics, stone location, treatment 
details, postoperative outcomes and complications were 
recorded. Inverse-probability-weighted regression adjust-
ment (IPWRA) analyses were conducted on outcome from 
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small stone fragments generated during laser fragmentation 
with the exit of irrigation fluid. Nevertheless, the use of the 
UAS can itself cause damage to the ureter by over disten-
sion which compromises ureteral blood flow, resulting in 
ureteral ischemia [6] or direct damage to the ureter during 
the insertion of the UAS [7].
The CROES initiated the Ureteroscopy (URS) Global 
Study to establish a prospective global database to examine 
the worldwide use of URS and determine factors affecting 
outcome. In the currently presented study, inverse-prob-
ability-weighted regression adjustment (IPWRA) is used 
to describe differences in stone-free rate (SFR) of patients 
who underwent URS treatment for their renal stones, with 
or without the use of a UAS.
Patients and methods
Study population
The URS Global Study is a prospective, observational, 
international, multicenter study with data collected on con-
secutive patients treated with URS over a 1-year period 
at each participating center. The overall study period was 
from January 2010 until October 2012. Centers were asked 
to treat patients according to their local protocols. Institu-
tional Research Board (IRB) or Institutional Ethics Com-
mittee approval was obtained by all participating centers 
before the start of the study. If IRB was not needed, the 
centers followed the protocol according the rules of Good 
Clinical Practice.
Patients who were eligible for inclusion in the present 
analysis were those who were candidates for flexible URS 
for renal stones as a primary treatment or after failure of a 
previous treatment and aged ≥18 years. No specific exclu-
sion criteria were applied. Details of treatment includ-
ing secondary treatment and patient follow-up have been 
described previously [8].
Assessment
Data were encrypted and collected electronically through 
a web-based Web site: www.croesoffice.org and held in a 
central database at the CROES office. Data included patient 
epidemiological characteristics, calculus specification, type 
of treatment, and postoperative outcomes and complica-
tions. Stone burden was calculated as the sum of all stone 
sizes (length × width × 0.25 × 3.14159). The classifica-
tion of a patient being stone free (SFR) was based on the 
absence of stones or fragments >1 mm. Operating time 
was defined as the time from the insertion of the endoscope 
until the insertion of a bladder catheter. Treatment failure 
was defined as stone still in situ, remaining stone fragments 
>1 mm, and failed access. Treatment success was defined 
as a patient free of stones >1 mm.
Confounders
Preoperative possible confounders were body mass index 
(BMI), age, gender, stone location, stone size, stone bur-
den, American Society of Anesthesiologists (ASA) score, 
preoperative stent placement, anticoagulant and antibiotics 
use, comorbidities such as diabetes, cardiovascular disease 
(CVD), prednisone use, Crohn’s disease, renal congeni-
tal abnormalities, a solitary kidney, case volume and aca-
demic status of the operating center. Intra-operative possi-
ble confounders were type or URS, type of fragmentation 
device, operation time, intra-operative complications and 
a postprocedural stent placement. Postoperative possible 
confounders were the method of evaluation, the length of 
hospital stay, retreatment, readmission and postoperative 
complications.
Statistical analysis
Inverse-probability-weighted regression adjustment 
(IPWRA) analyses were performed to determine whether 
there was a difference in SFR between using and not using 
of a UAS, independent from well-known possible con-
founders. Inversed probability weighting (IPW) is a method 
in which each observation is weighted by the propensity 
score of individual observations. If a subject had a higher 
probability of being in a group (using UAS or not), it was 
considered as overrepresented and therefore was given 
a lower weight. Alternatively, if the patient had a smaller 
probability of being in the group, it was considered as 
underrepresented and was given a higher weight. Gener-
ally, in an observational study, the weighting adjustment 
removes sampling bias [9]. Subsequently, IPWRA is a 
regression analysis in which preoperative characteristics-
based inverse probability weights are used in a regression 
model describing the relationship of interest.
Results
Patient characteristics
A total of 2239 patients with renal stones were treated with 
flexible URS. Of these 1494 (67 %) patients were treated 
with the use of a UAS and 745 (33 %) without a UAS. 
Baseline characteristics are shown in Table 1. Overall, sub-
jects treated with an UAS have higher preoperative ASA 
scores and larger stones.
Additionally, the UAS was most often used in North 
America (71.9 %), and South America (76.1 %), compared 
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Table 1  Preoperative characteristics of patients with renal stones treated with a flexible ureteroscopy (URS) with or without the assistance of a 
ureteral access sheath (UAS)
Parameter Patients treated with UAS
(n = 1494)













 Male, n (%) 901 (60.3) 462 (62.0) 1363 (60.9)

























































Renal stone location, n (%)
 Upper pole 115 (7.9) 63 (8.6) 178 (8.1) NS
 Mid pole 118 (8.1) 78 (10.6) 196 (9.0)
 Lower pole 505 (34.9) 271 (36.8) 776 (35.5)
 Renal pelvis 253 (17.5) 130 (17.7) 383 (17.5)






Stone size, n (%)
 <10 mm 720 (51.9) 458 (65.8) 1178 (56.6) P < 0.01
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with Asia (67.3 %), Western Europe (66.1 %) and Eastern 
Europe (58.3 %). Systematic use (≥80 % of the proce-
dures) of a UAS occurred in 39 centers (47 %), and never 
in 14 centers (17 %).
Operating parameters
Intra-operative characteristics are shown in Table 2. More 
patients were treated flexible URS alone in the UAS group 
and more patients with flexible plus semirigid URS in the 
non-UAS group. Also, size of the stones is larger in the 
UAS group, complication rates differ between the groups, 
and operating time is longer in the UAS group. Laser frag-
mentation was the most common form of stone disruption 
used.
Postoperative outcome and complications are shown 
in Table 3
Stone-free rates were 73.3 versus 59.3 % for the smaller 
stones and 81.5 versus 84.9 % for larger stones with and 
without a UAS, respectively; SFRs were lower with the use 
of a UAS (73.9 vs. 82.8 %). Higher SFR is most outspoken 
in cases with multiple stone locations. Also, hospital stay is 
longer in cases treated with an UAS.
Regression analysis
Of the total study population, only those who had complete 
information (n = 1827) were used in the regression analy-
sis. The IPWRA analyses based on both treatment and out-
come models are shown in Table 4. In this model, it was 
found that if none of the URS procedures were performed 
with the use of an UAS, the average stone-free rate would 
be 0.504, i.e., as much as 50 % of the population would be 
stone free. In addition, if all of the URS procedures were 
performed with the use of an UAS, the average stone-free 
rate would be 0.753, i.e., as much as 75 % of the popula-
tion would be stone free. This difference of 25 %, however, 
representing the average treatment effect, was not signifi-
cant (ATE: 0.248; P = 0.604). Using the IPWRA analysis 
on only the treated population in the estimations revealed 
no significant difference between using and not using of a 
UAS (31 %; ATET: 0.311; P = 0.523).
Table 1  continued
Parameter Patients treated with UAS
(n = 1494)





Renal congenital abnormality, n (%) 105 (7.0) 40 (6.4) 145 (6.5) NS
 Horse shoe 18 (1.2) 4 (0.5) 22 (1.0)
 Ectopic 4 (0.3) 4 (0.5) 8 (0.4)






Preoperative stent, n (%) 533 (35.8) 284 (38.4) 816 (36.7) NS
 Double J 511 (95.9) 278 (98.2) 789 (96.7)
 Single J 8 (1.5) – 8 (1.0)






ASA score, n (%)
 I 512 (36.4) 267 (41.4) 779 (38.0) P ≤ 0.01
 II 649 (46.2) 266 (41.2) 915 (44.6)
 III 228 (16.2) 105 (16.3) 333 (16.2)






Case volume, n (%)
 Low-volume center 314 (21.0) 149 (20.0) 463 (20.7) NS






Sample sizes for which data were available are shown in parenthesis
Group differences were tested with a t test for continuous variables, a Chi-square test for dichotomous and an ANOVA for categorical variables
BMI body mass index, DM diabetes mellitus, CVD cardiovascular disease, PCNL percutaneous nephrolithotomy, SWL extracorporeal shockwave 
lithotripsy, URS ureteroscopy, UPJ ureteropelvic junction, ASA American Society of Anesthesiologists
a Stone burden was calculated as the sum of all stone sizes (length × width × 0.25 × 3.14159)
2141World J Urol (2015) 33:2137–2144 
1 3
Discussion
Flexible URS is currently recommended by the Euro-
pean Association of Urology Urolithiasis Guidelines for 
the treatment of renal stones sized up to 1.5 cm [10]. Of 
note, currently most urologists recommend ‘dusting’ kid-
ney stones when using flexible URS rather than fragmen-
tation and removal of fragments, especially when treating 
larger sized stones. Consequently, one may question differ-
ences in outcome of SFR depending on the application of 
fragmentation or dusting of the stone. Whereas in smaller 
sized stones, depending on the localization and composi-
tion either dusting or fragmentation is used, in larger sized 
stones often the use of dusting followed by fragmentation 
is applied. At the very end, the SFR is based on the frag-
ments left following fragmentation. An UAS can be most 
instrumental to remove the multitude of fragments.
Reports have been made that the use of the UAS impacts 
on SFRs following flexible URS. L’Esperance et al. [1] 
conducted a retrospective review of 256 ureteroscopy pro-
cedures for the removal of renal calculi performed between 
1997 and 2003 (173 with UAS and 83 without). The groups 
were similar in age, sex and stone burden. Overall SFRs 
were 79 and 67 % in the UAS group and non-UAS group, 
respectively (P = 0.042). In contrast, reports from Ber-
quet et al. [11] (86 % in UAS group vs. 87 % in non-UAS 
group; n = 280) and Kourambas et al. [2] (78 % in the 
UAS groups vs. 85 % in non-UAS group; n = 59) reported 
no difference in SFRs with or without a UAS. In the cur-
rent study with large patient population, SFR was 73.9 % in 
the UAS group versus 82.8 % in the non-UAS group. This 
indicates an UAS is not primarily used to increase SFR. 
However, there were a number of limitations to the study. 
One limitation is that the reason to use an UAS, such as 
fragments removal, facilitate access or decrease intra-renal 
pressure, was not recorded, and consequently, the primary 
reason for its use was unknown. Besides possible added 
efficacy of the use of an UAS, also the added safety of the 
Table 2  Intra-operative characteristics of patients with renal stones treated with a flexible ureteroscopy (URS) with or without the assistance of 
a ureteral access sheath (UAS)
Sample sizes for which data were available are shown in parenthesis
Group differences were tested with a t test for continuous variables, a Chi-square test for dichotomous and an ANOVA for categorical variables
Parameter Patients treated with UAS
(n = 1494)





Type of URS, n (%) P < 0.01
 Flexible 973 (65.1) 416 (55.8) 1389 (62.0)






Fragmentation device, n (%)
 Laser 1304 (87.9) 609 (82.2) 1913 (86.0) NS
 Other 13 (0.8) 16 (2.1) 29 (1.3)













Stone size sub-categories, n (%) P ≤ 0.01
 <10 mm 720 (51.9) 458 (65.8) 1178 (56.6)






Intra-operative complication, n (%) NS
 Uneventful 1402 (94.1) 706 (94.9) 2108 (94.4)
 Failed 12 (0.8) 13 (1.7) 25 (1.1)
 Bleeding 31 (2.1) 9 (1.2) 40 (1.8)
 Perforation 17 (1.1) 9 (1.2) 26 (1.2)
 Other 5 (1.0) 10 (1.3) 30 (1.3)




(n = 744) –(n = 2234)
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Table 3  Postoperative characteristics of patients with renal stones treated with a flexible ureteroscopy (URS) with or without the assistance of a 
ureteral access sheath (UAS)
Parameter Patients treated with access sheath
(n = 1494)











SFR by location sub-categories, n (%):
 Upper pole 84 (76.4) 52 (83.9) 136 (79.0) NS
 Mid pole 97 (84.3) 69 (89.6) 166 (86.5) NS
 Lower pole 386 (79.8) 222 (82.8) 608 (80.9) NS
 Renal pelvis 188 (78.3) 102 (82.9) 290 (79.9) NS







SFR by stone size sub-categories, n (%)
 <10 mm 118(73.3) 269 (59.3) 387 (62.9) NS







Method of evaluation, n (%) NS
 Ultrasound 572 (38.8) 331 (44.7) 903 (40.7)
 X-ray/KUB 724 (49.1) 285 (38.5) 1009 (45.5)
 CT 292 (19.8) 83 (11.2) 375 (16.9)
 IVU 81 (5.5) 20 (2.7) 101 (4.6)
 Retrograde pyelogram 20 (1.4) 66 (8.9) 86 (3.9)
 Intra-operative confirmation 246 (16.7) 99 (13.4) 345 (15.6)
 Other 16 (1.1) 4 (0.5) 20 (0.9)



























Complication according to stone  
location sub-categories, n (%):
NS
 Upper pole 8 (7.1) 5 (12.5) 13 (8.6)
 Mid pole 12 (10.7) 4 (10.0) 16 (10.5)
 Lower pole 32 (28.6) 12 (30.0) 44 (28.9)
 Renal pelvis 22 (19.6) 10 (25.0) 32 (21.1)






Complication according to stone size 
sub-categories:
NS
 <10 mm 52 (48.6) 24 (60.0) 76 (51.7)






Total postoperative complications,  
n (%)
115 (7.7) 40 (5.4) 155 (6.9) P = 0.041
 Bleeding 9 (5.6) 4 (8.7) 13 (5.9)
 Fever 46 (28.6) 18 (39.1) 64 (29.4)
 UTI 30 (18.6) 11 (23.9) 41 (18.8)
 Bladder cramps 13 (8.1) 5 (10.9) 18 (16.2)
 Lung embolism 1 (0.6) – 1 (0.5)
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use of an UAS without increased risk of ureteral damage 
is important. From Table 2 in the present work one can 
conclude that UAS usage did not increase the risk of ure-
teral damage (perforation 1.1 vs. 1.2 %) nor bleeding (2.1 
vs. 1.2 %), whereas Table 3 shows the reduced incidence 
of postoperative infectious complications (fever, UTI, sep-
sis 28.6, 18.6 and 4.3 % vs. 39.1, 23.9 and 15.2 % for the 
UAS vs. the non-UAS group accordingly). Noteworthy is 
that several UAS are marketed involving different lengths, 
sizes and characteristics, which relate to ureter status and 
anatomy. A study on compatibility of the different UASs 
with flexible URS showed the 12/14 F UAS to be a “uni-
versal” UAS that accepts the currently available flexible 
ureteroscopes [12]. But the smaller sized ureteroscopes 
have fueled the development of smaller sized UAS; at pre-
sent 10/12 and 11/13 are predominantly used [12], result-
ing in less complications.
Another limitation may be the evaluation of SFR. We are 
aware that standardization of evaluation of stone manage-
ment is often lacking. This has been highlighted in a recent 
communication on standardization on terminology follow-
ing PCNL [13]. Ideally, a CT scan can best evaluate SFR 
following ureteroscopy. In the present real-life work, the 
SFR was evaluated by CT in a limited number of cases, 
whereas otherwise plain abdominal X-ray, renal ultrasound 
or intra-operative findings were used.
Finally, a more obvious limitation is the lack of rand-
omization. As the subject characteristics between treatment 
groups (UAS or non-UAS) were imbalanced, the direct 
comparison of treatment groups was inappropriate. To 
overcome this, the IPWRA method [14] was used to deter-
mine whether the use an UAS impacted on SFR and cor-
recting this for intra- and postoperative characteristics. The 
results showed no significant difference in SFR between 
the using and not using of a UAS.
In conclusion, in the URS Global Study there was no 
difference in SFR when a UAS was used or not. This result 
was independent from baseline characteristics and cor-
rected for possible intra- and postoperative confounders. 
Intra-operative complication rates were favorable for the 
UAS group, including less ureteral damage or bleeding.
Sample sizes for which data were available are shown in parenthesis
Group differences were tested with a t test for continuous variables, a Chi-square test for dichotomous and an ANOVA for categorical variables
CT computed tomography, KUB kidneys, ureters and bladder, IVU intravenous urography, UTI urinary tract infection, CVA cardiovascular 
accident
Table 3  continued
Parameter Patients treated with access sheath
(n = 1494)




 CVA – 1 (2.2) 1 (0.5)
 Sepsis 7 (4.3) 7 (15.2) 14 (6.4)
 Acute abdomen 2 (1.2) – 2 (0.9)















Table 4  Results of the inverse-probability-weighted regression 
adjustment
Stone-free status Coefficient SE P value 95 % CI
Potential outcome means (POM)
 AccSh
  No (0) A 0.504 0.478 0.291 −0.432, 1.441
  Yes (0) B 0.753 0.012 0.000 0.730, 0.776
Outcome model (0) for the non-treated
 Operating time 0.000 0.000 0.620 0.000, 0.000
 Intra-operative  
complications
−0.306 2.468 0.901 −5.143, 4.530
 Postoperative  
complications
0.845 1.483 0.569 −2.062, 3.751
 Constant −0.035 2.088 0.986 −4.127, 4.056
Outcome model (1) for the treated
 Operating time 0.000 0.000 0.119 0.000, 0.000
 Intra-operative  
complications
−0.237 0.842 0.779 −1.887, 1.414
 Postoperative  
complications
−0.957 0.867 0.270 −2.656, 0.742
Constant 1.194 0.069 0.000 1.058, 1.329
Treatment model
 Stone burden 0.000 0.001 0.999 −0.002, 0.002
 Stone location 0.099 0.039 0.012 0.022, 0.176
 Stone size 0.054 0.028 0.059 −0.002, 0.110
 Previous treatment 0.201 0.112 0.074 −0.019, 0.420
 Academic center −0.252 0.112 0.024 −0.472, −0.033
 Case volume −0.002 0.000 0.000 −0.002, −0.001
 Constant 0.370 0.227 0.103 −0.075, 0.815
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